India, Jan. 29 -- While reporting financial results for the fourth quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) initiated its adjusted earnings and revenue guidance for the full-year 2025.
For fiscal 2025, the company now projects adjusted earnings in a range of $2.35 to $2.65 per share on revenues between $16.8 billion and $17.4 billion.
On average, analysts polled expect the company to report earnings of $2.78 per share on revenues of $17.09 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported a net loss attributable to Teva of $217 million or $0.19 per share, compared to net income of $461 million or $0.41 per share in the prior-year quarter.
Exclud...